SCYNEXIS (SCYX)
(Delayed Data from NSDQ)
$1.56 USD
-0.07 (-4.29%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.56 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SCYX 1.56 -0.07(-4.29%)
Will SCYX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SCYX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SCYX
Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?
PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?
SCYX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue Estimates
Avalo Therapeutics, Inc. (AVTX) Reports Q2 Loss, Misses Revenue Estimates
Other News for SCYX
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
Buy Rating Affirmed for SCYNEXIS Amid Antifungal Progress and Market Potential
SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024
Wall Street Analysts Are Bullish on Top Healthcare Picks
Scynexis: Q2 Earnings Snapshot